159 related articles for article (PubMed ID: 36618369)
1. Corrigendum: Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1082984. PubMed ID: 36618369
[TBL] [Abstract][Full Text] [Related]
2. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers.
Feng Q; Sun B; Xue T; Li R; Lin C; Gao Y; Sun L; Zhuo Y; Wang D
Front Immunol; 2022; 13():1025608. PubMed ID: 36341440
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2019; 10():780. PubMed ID: 31049049
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum: Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells.
Dwivedi A; Karulkar A; Ghosh S; Rafiq A; Purwar R
Front Immunol; 2019; 10():401. PubMed ID: 30906295
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers.
Lü P; Qiu S; Pan Y; Yu F; Chen K
Cancer Biother Radiopharm; 2021 May; 36(4):307-315. PubMed ID: 33481647
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Ligand-based CAR T-cell: Different strategies to drive T-cells in future new treatments.
Ramírez-Chacón A; Betriu-Méndez S; Bartoló-Ibars A; González A; Martí M; Juan M
Front Immunol; 2022; 13():1078003. PubMed ID: 36479103
[TBL] [Abstract][Full Text] [Related]
7. A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer.
Ali AI; Wang M; von Scheidt B; Dominguez PM; Harrison AJ; Tantalo DGM; Kang J; Oliver AJ; Chan JD; Du X; Bai Y; Lee B; Johnstone RW; Darcy PK; Kershaw MH; Slaney CY
Clin Cancer Res; 2021 Nov; 27(22):6222-6234. PubMed ID: 34475103
[TBL] [Abstract][Full Text] [Related]
8. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1243241. PubMed ID: 37662957
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Gil-Alós D; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1349296. PubMed ID: 38268917
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
Front Immunol; 2020; 11():628776. PubMed ID: 33365036
[TBL] [Abstract][Full Text] [Related]
11. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
12. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.
Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy.
Chiriaco C; Donini C; Cortese M; Ughetto S; Modica C; Martinelli I; Proment A; Vitali L; Fontani L; Casucci M; Comoglio PM; Giordano S; Sangiolo D; Leuci V; Vigna E
J Exp Clin Cancer Res; 2022 Oct; 41(1):309. PubMed ID: 36271379
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
16. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
19. PSCA is a target of chimeric antigen receptor T cells in gastric cancer.
Wu D; Lv J; Zhao R; Wu Z; Zheng D; Shi J; Lin S; Wang S; Wu Q; Long Y; Li P; Yao Y
Biomark Res; 2020; 8():3. PubMed ID: 32010446
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum: Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes.
Obarorakpor N; Patel D; Boyarov R; Amarsaikhan N; Cepeda JR; Eastes D; Robertson S; Johnson T; Yang K; Tang Q; Zhang L
Front Immunol; 2024; 15():1391518. PubMed ID: 38524122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
